Acadia Pharmaceuticals Announces DAYBUE® STIX is Now Broadly Available in the United States for the Treatment of Rett Syndrome
Acadia Pharmaceuticals Announces DAYBUE® STIX is Now Broadly Available in the United States for the Treatment of Rett Syndrome
Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union
Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026
QIMC Intersects Major Fault Breccia System in DDH-26-03 at West Advocate and Reports Elevated Hydrogen 2.5 km from the Initial Discovery
Copper Intelligence announces Acquisition of the Kitungu Project - PR 15880 - in the Democratic Republic of Congo copper belt
Harvest Gold Provides Comprehensive Update: Rosebud Project , Mosseau Agreement With Vior, And Eight-Month Progress Report On Urban Barry Belt Properties
NEW QUEBEC GRAPHITE TRANSFORMATION STUDY FOR LAC CARHEIL PROJECT DELIVERS IMPRESSIVE ECONOMIC RESULTS
Canada One Announces 2026 Two-Phase Exploration Program to Advance High-Priority Porphyry Targets at Copper Dome
